Skip to main content
Download PDF

SARS-CoV-2 S protein activates NLRP3 inflammasome and deregulates coagulation factors in endothelial and immune cells

Cell Communication and Signaling volume 22, Article number: 38 (2024) Cite this article

A Correction to this article was published on 23 January 2024

This article has been updated

Abstract

Background

Hyperinflammation, hypercoagulation and endothelial injury are major findings in acute and post-COVID-19. The SARS-CoV-2 S protein has been detected as an isolated element in human tissues reservoirs and is the main product of mRNA COVID-19 vaccines. We investigated whether the S protein alone triggers pro-inflammatory and pro-coagulant responses in primary cultures of two cell types deeply affected by SARS-CoV-2, such are monocytes and endothelial cells.

Methods

In human umbilical vein endothelial cells (HUVEC) and monocytes, the components of NF-κB and the NLRP3 inflammasome system, as well as coagulation regulators, were assessed by qRT-PCR, Western blot, flow cytometry, or indirect immunofluorescence.

Results

S protein activated NF-κB, promoted pro-inflammatory cytokines release, and triggered the priming and activation of the NLRP3 inflammasome system resulting in mature IL-1β formation in both cell types. This was paralleled by enhanced production of coagulation factors such as von Willebrand factor (vWF), factor VIII or tissue factor, that was mediated, at least in part, by IL-1β. Additionally, S protein failed to enhance ADAMTS-13 levels to counteract the pro-coagulant activity of vWF multimers. Monocytes and HUVEC barely expressed angiotensin-converting enzyme-2. Pharmacological approaches and gene silencing showed that TLR4 receptors mediated the effects of S protein in monocytes, but not in HUVEC.

Conclusion

S protein behaves both as a pro-inflammatory and pro-coagulant stimulus in human monocytes and endothelial cells. Interfering with the receptors or signaling pathways evoked by the S protein may help preventing immune and vascular complications driven by such an isolated viral element.

Video Abstract

Background

Corona Virus Disease 2019 (COVID-19), was reported from Wuhan city, China, and has caused over 750 million confirmed infections and nearly 7 million deaths worldwide according to the World Health Organization Coronavirus (COVID-19) Dashboard [1]. The enormous impact of COVID-19 and its sequalae on human health and the socioeconomic system [2] has raised massive interest in better understanding the pathophysiological mechanisms of the disease.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the COVID-19 pandemia, is a member of the coronavirus family. As such it is covered by a crown of spike (S) protein, which is composed of two main domains, S2 and S1 [3, 4]. The latter contains the receptor binding domain (RBD) that forms a trimer and attaches to the host cell receptor, while the S2 domain mediates viral cell membrane fusion and entry [3, 4]. Angiotensin converting enzyme 2 (ACE2) was initially identified as a major receptor allowing for SARS-CoV-2 entry in different human cell types [5, 6]. However, other cell surface molecules have been acknowledged to mediate the recognition between the viral S protein and host cells, including toll-like receptor 4 (TLR4), basigin or cluster of differentiation (CD) 147, and dipeptydilpeptidase-4 or CD26 [7, 8]. Also, the concept has emerged that specific viral elements alone, including the S protein, might interact with host cell receptors to trigger intracellular responses [9].

Together with the description of respiratory symptoms and acute respiratory distress syndrome (ARDS), very early since the beginning of the COVID-19 pandemia, endothelial injury was a primary finding in patients infected by SARS-CoV-2 [10]. Postmortem histology revealed viral inclusions in endothelial apoptotic cells, microvascular lymphocytic endotheliitis, and the infiltration of inflammatory immune cells around the vessels and the endothelial layer together with microthrombi formation [11, 12]. Since then, a large series of clinical observations have identified the vasculature as one of the main trans-organ systems affected by SARS-CoV2 infection as well as a major cause of sequalae following COVID-19 [13, 14].

Inflammatory responses in severe COVID-19 patients are characterized by intense immune cell recruitment and enhanced levels of inflammatory markers including C-reactive protein, ferritin and cytokines, associated with hyper-coagulation state [15, 16]. Elevated circulating levels of pro-coagulant factors such as von Willebrand factor (vWF), factor VIII (FVIII) or tissue factor (TF) were found in a high number of patients with COVID-19 [17, 18]. While FVIII and vWF are mainly produced by endothelial cells, TF can also be released by other activated cell types, particularly activated immune cells [19]. The coordinated study of inflammatory and coagulant factors that trigger endothelial hyper-activation and thrombosis seems nowadays essential to understand the complex pathophysiology of COVID-19 and its sequalae and to design more rationale and better targeted therapeutical treatments.

The NLR family pyrin domain-containing 3 (NLRP3) inflammasome system, a first-line sensor of the innate immune response, is currently considered as a key driver of vascular inflammation and endothelial dysfunction [20] and a relevant player in multiple pathologies including atherosclerosis and other cardiovascular diseases [21], diabetes mellitus [22], obstructive sleep apnea [23], or viral infections including COVID-19 [24]. After a first priming phase to enhance some cellular components of the system, such as NLRP3 or the inactive precursor of interleukin-1β (pro-IL-1β), the inflammasome need to assemble into a functional multi-protein structure involving NLRP3 and other proteins, including adaptor molecule apoptosis-associated speck-like protein (ASC). This, in turn, leads to the activation of caspase-1, which cleaves pro-IL-1β and pro-IL-18 into their mature active forms [25] and, in monocytes/macrophages, triggers gasdermin D activation, favoring the formation of pores in the cell membrane that permit the release of pro-inflammatory cytokines [26, 27]. In the context of COVID-19 disease, activation of NLRP3 inflammasome can be triggered by the massive liberation of proinflammatory cytokines [28]. However, the role of other activators, such as the viral S protein, which has been detected in the circulation of infected patients or in tissues after SARS-CoV-2 infection [29] and is the main product of mRNA vaccines against COVID-19, remains elusive.

The aim of the present study was to address whether the SARS-CoV2 S protein can, as an isolated viral element, directly activate pro-inflammatory and pro-thrombotic signaling in primary human endothelial and immune cell cultures, with special attention to the role of the NLRP3 inflammasome activation and the release of pro-coagulant factors.

Material and methods

(for more details, please see Supplemental Material)

Human umbilical vein endothelial cells culture

Human umbilical vein endothelial cells (HUVEC) were isolated from umbilical cords from donors at Hospital Universitario La Paz (Spain, Madrid) with informed consent, following the Spanish legislation and under approval of the appropriate Research Ethics Committee as previously described [30].

PBMCs, monocytes isolation and cell cultures

Peripheral blood mononuclear cells (PBMC) and monocyte isolation and culture were obtained by venipuncture from peripheral vein from healthy subjects (aged 18–65) as described in Supplemental Methods.

Western blot

HUVEC or enriched monocytes were lysed and protein lysates were separated and quantified by Western blot [31], as described in Supplemental Methods.

Visualization of NLRP3 activation by indirect immunofluorescence

Once NLRP3 inflammasome activation is triggered, the ASC protein assembles, and forms toroidal structures known as specks [32] that were visualized in HUVEC by indirect immunofluorescence, as previously described [33].

TLR4 and NLRP3 inhibition assays

The pharmacological inhibition of TLR4 and NLRP3 inflammasome by means of TAK242 and MCC950, respectively, and TLR4 silencing were performed as described in Supplemental Methods.

Statistical analysis

Variables were analyzed for normality using Shapiro-Wilks’ test. For variables presenting normality, mean differences were evaluated using paired t-test, for pairs comparisons, and using repeated measures ANOVA (R-M-ANOVA) with Tuckey’s test multiple comparison, for more than two groups comparison. For variables not presenting normality, the Wilcoxon’s test was used to assess differences between two groups. In line, the Friedman’s test was used to analyze differences among more than two groups, including the Dunn’s test for multiple comparisons.

Results

S protein promotes the priming of the NLRP3 inflammasome in HUVEC

In HUVEC exposed to S protein (7, 35 and 70 nM) a concentration-dependent increase in the protein levels of both NLRP3 and pro-IL-1β was observed from a threshold concentration of 35 nM (Fig. 1A and B). The expression of pro-caspase-1 was equally enhanced by S protein (Fig. 1C), while ASC levels remained unchanged (Fig. 1D). The pro-inflammatory cytokine IL-1β (2.5 ng/mL) elicited similar effects on the priming of the different NLRP3 inflammasome components (Figs. 1A to D).

Fig. 1
figure 1

S protein promotes NLRP3 priming and NF-κB activation in primary HUVEC cultures. Human umbilical vein endothelial cells (HUVEC) were treated with viral S protein at 7, 35 and 70 nM and IL-1β at 2.5 ng/mL for 18 h and the protein levels of the NLRP3 inflammasome system components A NLRP3 (n = 5), B pro-IL-1β (n = 4), C pro-casp-1 (n = 5), and D ASC protein levels (n = 3) were analyzed in total cell lysates by Western blot. In addition, NF-κB activation was quantified by means of E phospho-p65 (P-p65) protein levels by Western blot (n = 3) and F visualized by indirect immunofluorescence as the translocation of p65 (green) to cell nuclei countersatained with DAPI (blue). Representative images from confocal microscopy of p65 immunofluorescence staining are shown. Scale bar represents 50 μm (G). For quantification of cells with nuclear localization of p65 at least 200 cells per treatment were counted (n = 4). For Western blots, representative gels are shown on top of the corresponding graphs, with β-actin used as a loading control. Bar graphs represent mean ± SEM. Statistical differences were analyzed by t-test. *p < 0.05 versus unstimulated control

Full size image

S protein activates NF-κB in HUVEC

Since nuclear factor-kappa B (NF-κB) is a major transcription factor in inflammatory responses that can regulate the expression of several NLRP3 inflammasome components [28], we next assessed the capacity of SARS-CoV2 S protein to activate the NF-κB pathway. Fig. 1E shows how S protein increased in a concentration-dependent manner the levels of phosphorylated-p65 (pp65) used as a marker of NF-κB activation. The translocation of active pp65 from the cytoplasm to the nucleus was visualized by indirect immunofluorescence (Fig. 1F) and quantified by image analysis (Fig. 1G). IL-1β (2.5 ng/mL) was used as a positive control of NF-κB activation (Figs. 1E to G).

S protein promotes the activation of the NLRP3 inflammasome in HUVEC

Upon activation, NLRP3 protein oligomerizes and interacts with ASC to assemble into a multiprotein scaffold (ASC speck) wherein caspase-1 is activated to process pro-IL-1β and pro-IL-18 into their mature forms [32]. Indeed, S protein (35 nM) promoted the formation of such toroidal-shaped specks characteristic of assembled and functional NLRP3 inflammasome as visualized by ASC protein immunostaining (Fig. 2A) and its subsequent quantification (Fig. 2B). In accordance, higher levels of active caspase-1 and mature IL-1β were also found in endothelial cells stimulated with increasing concentrations of the viral S protein (Fig. 2C and D, respectively). IL-1β levels were found enhanced in cell supernatants (Fig. 2E), while no significant changes were observed in the cellular content of the protein gasdermin D (GSDMD) or its pore-forming N-terminal cleavage product (GSDMD-NT) after S protein or stimulation IL-1β (Fig. 2F).

Fig. 2
figure 2

S protein promotes the activation of the NLRP3 inflammasome in HUVEC. Human umbilical vein endothelial cells (HUVEC) were treated with viral S protein (35 nM), IL-1β (2.5 ng/mL) or the S1 fragment of S protein (35 nM) for 18–24 h. A The formation of toroidal specks corresponding to activated NLRP3 inflammasome were visualized by indirect immunofluorescence against ASC (red) using a confocal microscope. Nuclei were counter-stained with DAPI (blue). Scale bar represents 50 μm B NLRP3 inflammasome activation was quantified by manual blind scoring of 27 radial distributed fields per sample as the number of ASC speck-positive cells. White arrows indicate speck positive cells. Scale bar represents 50 μm. In addition, the cellular protein levels of C active cleaved caspase-1 (casp-1) (n = 6) and D mature IL-1β (n = 4). E IL-1β released to the cell supernatants was quantified by ELISA (n = 5–8). F Gasdermin D (GSDMD) and cleaved GSDMD-NT (n = 8) were determined by Western blot in total cell lysates from HUVEC treated with 7, 35 and 70 nM S protein or 2,5 ng/mL IL-1β. Representative gels are shown on top of the corresponding graphs, with β-actin used as a loading control. Bar graphs represent mean ± SEM. Statistical differences were analyzed by t-test. *p < 0.05 versus control with no S protein

Full size image

We next studied whether the S1 fragment of the S protein, which contains the RBD that binds the host cell receptors, was sufficient to trigger NLRP3 inflammasome activation in HUVEC. The S1 fragment did not induce the formation of ASC-specks by itself (Fig. 2A and B), suggesting that the whole S protein or at least a trimeric S1 conformation may be required to exert such an activation of the NLRP3 inflammasome complex.

S protein enhances the levels of coagulation factors and reduces ADAMST-13 availability in HUVEC

Endothelial cells can synthesize and release a number of key pro-coagulant proteins that can participate in prothrombotic events. HUVEC challenged with the S protein exhibited a concentration-dependent increase in the vWF content as determined by Western blot (Fig. 3A). Moreover, as visualized by immunofluorescence, vWF was detected in intracellular granules but also in the extracellular space forming multimeric filaments, which were mainly visible in cultures stimulated with the S protein (Fig. 3B). The increased secretion of vWF to the cell supernatants induced by the viral protein was confirmed and quantified by ELISA (Fig. 3C). IL-1β exerted similar effects on vWF levels and secretion, although with a less intense extracellular vWF filament staining (Figs. 3A to C). Additionally, IL-1β enhanced the endothelial content in A disintegrin and metalloprotease with a thrombospondin type 1 motif, member 13 (ADAMST-13), a primary molecular regulator that attenuates vWF activity by cleaving multimers [34], while this effect was not apparent in HUVEC exposed to S protein (Fig. 3D). In addition, S protein enhanced the content of FVIII and TF, an initiator of the extrinsic coagulation pathway, in HUVEC, as also did IL-1β (Fig. 3E and F).

Fig. 3
figure 3

The activation NLRP3 inflammasome and the release of IL-1β increase coagulation factors mediated by S protein. Human umbilical vein endothelial cells (HUVEC) were treated with viral S protein at 7, 35 and 70 nM or IL-1β at 2.5 ng/mL for 18 h. The levels of von Willebrand Factor (vWF) were determined A by Western blot in total cell lysates (n = 6), and B visualized in HUVEC stimulated with S (35 nM) or IL-1β (2.5 ng/mL) by indirect immunoflorescence (red). Representative images are shown in which vWF can be seen both as granules within the HUVEC cytoplasm and multimeric filaments in the extracellular space. Nuclei were counter-stained with DAPI (blue). Scale bar represents 50 μm. C vWF was also measured by ELISA in cell supernatants (n = 4). In the same experimental conditions, the protein levels of D ADAMTS-13, E FVIII, and F TF were quantified in total cell lysates by Western blot. Representative gels are shown on top of the corresponding graphs, with β-actin used as a loading control. Bar graphs represent mean ± SEM. Statistical differences were analyzed by t-test. *p < 0.05

Full size image

Because of the connection reported between inflammation and coagulation [35], we next addressed whether activation of the NLRP3 inflammasome pathway could be at the basis of the enhanced production of pro-coagulant factors induced by S protein. In the presence of the NLRP3 inflammasome inhibitor MCC950 (1 μM) a trend was observed towards the reduction of vWF (by 22.86%) and TF (by 44.34%) levels induced by S protein, although statistical significancy was not reached (Fig. S1A and S1B). However, the IL-1R blocker anakinra (1 μg/mL) significantly prevented the effect of the viral protein on TF levels and reduced vWF by 30.79% (Fig. S1B). As expected, anakinra blunted the stimulatory action of IL-1β thus confirming the capacity of the drug to block IL-1R receptors (Fig. S1A and S1B).

S protein activates NF-κB pathway and triggers NLRP3 inflammasome activation and TF release in human monocytes

We next studied the effects of the S protein in monocytes as key components of the innate immune response triggering pro-inflammatory pathways. We first performed an in vitro model using enriched human monocytes to determine the kinetic time-course of NF-κB expression (Fig. S2A) and found elevated NF-κB mRNA expression after cells were exposed to S protein (15 nM) for 16 h (Fig. 4A). The activation of the NF-κB pathway was confirmed by the increased pp65 levels (Fig. 4B and Fig. S2B). Active NF-κB is able to translocate to the nucleus where it triggers the transcription of several response genes including the tissue necrosis factor alpha (TNF-α) and IL-6 inflammatory cytokines. Accordingly, we observed increased TNF-α and IL-6 mRNA (Fig. 4C and Figs. S2C and S2D), together with higher protein levels of IL-6 in supernatants of monocytes treated with S protein (Fig. 4D). Altogether S protein triggered NF-κB pathway in human monocytes leading to inflammatory cytokines production.

Fig. 4
figure 4

NF-κB pathway and NLRP3 inflammasome components in S protein stimulated monocytes. Enriched monocytes from healthy donor were cultured under control conditions or stimulated with S protein 15 nM (S15). A NF-κB mRNA expression analysis by qPCR in enriched monocytes cultured for 16 h (n = 12). B Western blot protein values of phosphorylated NF-κB p65 particle (pp65) relative to β-actin protein values from lysates of enriched monocytes cultured for 16 hours (n = 3). C mRNA expression analysis by qPCR of TNF-α (n = 12) and IL-6 (n = 9) in enriched monocytes cultured for 3 hours. D IL-6 concentration in supernatant from enriched monocytes cultured for 16 hours (n = 12). E Left: CD14+ gated-cells normalized mean fluorescent intensity (MFI) of NLRP3 (n = 20); Right: normalized NLRP3 to β-actin protein ratio determined by Western blot from enriched monocyte’s lysates cultured for 16 hours (n = 7). F CD14+ gated cells normalized mean fluorescent intensity (MFI) of ASC (n = 12). G Normalized amount of active caspase positive (Casp-1+) CD14+ cells analyzed by flow cytometry from enriched monocytes cultured for 16 hours (n = 20). H Supernatant IL-1β concentration measured by CBA (n = 12). I Normalized TF to β-actin protein ratio determined by Western blot from enriched monocytes lysates cultured for 16 hours (n = 5). Differences were analyzed using Wilcoxon’s paired test. J Enriched monocytes were stimulated with S protein or control, treated or not with MCC950 and cultured for 16 h. Left: CD14+ gated-cells normalized mean fluorescent intensity (MFI) of NLRP3 (n = 12); center: normalized amount of Casp-1+ CD14+ cells analyzed by flow cytometry (n = 15); right: supernatant IL-1β concentration measured by CBA (n = 6). Differences were analyzed by repeated measures ANOVA and Tukey’s multiple comparison test. All data are represented as mean ± Standard Error of the Mean (SEM). Only statistically significant differences are stated: *p < 0.05, **p < 0.01., ***p < 0.001 and ****p < 0.0001

Full size image

NF-κB pathway is part of the NLRP3 inflammasome priming. In accordance with the results in HUVEC, we observed an increased NLRP3 expression in monocytes stimulated with S protein, as measured by flow cytometry and Western blot (Fig. 4E, Fig. S3A and Fig. S4A), together with an over-expression of ASC (Fig. 4F and Fig. S3B). Additionally, increased mRNA expression of inflammasome components (NLRP3, ASC, caspase-1) and TF was observed after S protein stimulation (Fig. S4B).

To assess the ability of S protein to also trigger NLRP3 inflammasome activation in human monocytes, we performed a FAM-FLICA caspase-1 assay which uses fluorescent inhibitor probe FAM-YVAD-FMK, capable of specifically labeling active caspase-1. By flow cytometry, we observed an elevated number of monocytes positively stained for active caspase-1 after stimulation by S protein (Fig. 4G and Fig. S3C). In accordance, IL- 1β levels were enhanced in the supernatants from monocytes treated with S protein as compared with untreated controls (Fig. 4H). Moreover, treated monocytes presented increased levels of TF, measured by Western blot (Fig. 4I and Fig. S4C). Finally, to assess the role of NLRP3 inflammasome in the S protein-triggered increase of active caspase-1 and supernatant IL-1β, we performed an experiment including the specific NLRP3 inhibitor MCC950, which was capable to reduce NLRP3 expression and to limit active caspase-1 production and IL-1β release by monocytes stimulated with S protein (Fig. 4J). Moreover, the use of caspase-1 inhibitor, Ac-YVAD-cmk, reduced the cellular content of caspase-1 as well as the amount of IL-1β in cell supernatants, minimizing S protein effect (Fig. S4D). Altogether the data point out the ability of S protein to trigger the priming and activation of NLRP3 inflammasome in human monocytes, resulting in the release of active inflammatory cytokines and the production of TF, which is involved in the coagulation cascade.

TLR4 receptors mediate the pro-inflammatory and pro-coagulant action of S protein in monocytes but not in HUVEC

We next aimed to identify in monocytes and HUVEC potential cell receptors capable to interact with S protein to trigger NLRP3 inflammasome inflammation and the release of pro-coagulant factors. ACE2 has been proposed as one of the main human host cell receptors for SARS-CoV2 [5, 6]. However, its expression was not detectable in both HUVEC and PBMC primary cultures as assessed by real time-quantitative PCR (RT-qPCR) (Fig. S5).

Based on the capacity of S protein to prime and activate the innate immune system complex NLRP3 inflammasome, we next tested the implication of TLR4, a major receptor of this system abundantly expressed in monocytes and also present in cardiac and vascular cells [36]. In monocytes, resatorvid (TAK242; 5 μM), a selective TLR4 inhibitor, significantly reduced the upregulation of NF-κB mRNA (Fig. 5A) and the enhanced NF-κB p65 phosphorylation (Fig. 5B) induced by the S protein. Moreover, the drug prevented mRNA overexpression of TNF-α and IL-6 (Fig. 5C) and reduced the concentration of IL-6 in supernatants stimulated by S protein (Fig. 5D).

Fig. 5
figure 5

Effect of S protein stimulation over monocytes treated with TLR4 inhibitor TAK242. (A-I) Enriched monocytes from healthy donor were cultured for 16 h and were stimulated or not with S protein (S15) and treated or not with TLR4 inhibitor (TAK242). A NF-κB mRNA expression analysis by qPCR. (n = 9). B Western blot protein values of phosphorylated NF-κB p65 particle (pp65) relative to β-actin protein values (n = 3). C mRNA expression analysis by qPCR of TNF-α (n = 10) and IL-6 (n = 7). D IL-6 concentration in supernatant from enriched monocytes (n = 10). E Left: CD14+ gated-cells normalized mean fluorescent intensity (MFI) of NLRP3 (n = 20); right: normalized NLRP3 to β-actin protein ratio determined by Western blot (n = 7). F CD14+ gated cells normalized mean fluorescent intensity (MFI) of ASC (n = 12). G Normalized amount of active caspase positive (Casp-1+) CD14+ cells analyzed by flow cytometry (=20). H Supernatant IL-1β concentration measured by CBA (n = 12). I Normalized TF to β-actin protein ratio determined by Western blot (n = 5). Differences were analyzed by repeated measures ANOVA and Tukey’s multiple comparison test. J-K Enriched monocytes from healthy donor were transfected in absence (control) or presence of TLR4 siRNA (siTLR4) and cultured for 16 h with S15 or not. J Normalized amount of CD14+ cells expressing surface TLR4 (n = 7). K Left: CD14+ gated-cells normalized mean fluorescent intensity (MFI) of NLRP3 (n = 7): right: normalized amount of active casp-1+ CD14+ cells analyzed by flow cytometry (n = 7). Differences were analyzed using Wilcoxon’s paired test. All data are represented as mean ± SEM. Only statistically significant differences are stated: *p < 0.05, **p < 0.01, and ***p < 0.001

Full size image

Since TLR4 inhibition limited the activation of NF-κB, we next analyzed the impact of the drug on NLRP3 priming and activation. TAK242 abrogated the ability of S protein to overexpress NLRP3 at both protein (Fig. 5E and Fig. S4A) and mRNA expression level (Fig. S6A) and limited ASC expression induced by the viral protein (Fig. 5F and Fig. S6A). Accordingly, S protein was unable to trigger the accumulation of active caspase-1 (Fig. 5G) or the overexpression of caspase-1 mRNA (Fig. S6A) in the presence of TAK242. Lastly, TLR4 inhibition reduced the concentration of IL-1β in supernatants from monocytes stimulated with S protein (Fig. 5H), as well as TF protein levels (Fig. 5I and Fig. S4C) and TF mRNA expression induced by the viral protein (Fig. S6A). Altogether, TAK242 impaired the ability of S protein to activate NF-κB pathway and trigger NLRP3 inflammasome priming and activation, pointing out the importance of TLR4 receptor in the interaction of S protein with monocytes.

In order to confirm the observations obtained with the TLR4 pharmacological inhibition we next used a molecular approach, where we blocked TLR4 expression in monocytes using specific TLR4 short interfering RNA (siTLR4). After confirming by flow cytometry that TLR4 was indeed reduced in monocytes surface after transfection with siTLR4 (Fig. 5J), we observed that NLRP3 levels induced by S protein were limited in monocytes transfected with siTLR4 (Fig. 5K). Similarly, active caspase-1 accumulation caused by S protein was abrogated in siTLR4 monocytes (Fig. 5K). We also analyzed, by RT-qPCR, the effect of siTLR4 transfection in the mRNA expression of NLRP3 components. In accordance with the previous results, mRNA expression of NLRP3, ASC, caspase-1 and TF was reduced in siTLR4 monocytes stimulated with S protein compared to control monocytes equally stimulated (Fig. S6B).

Unlike to that observed in monocytes, the pharmacological TLR4 blockade with TAK242 in HUVEC primary cultures did not result in restricted priming or activation of the NLRP3 inflammasome (Figs. S7A and S7B) nor did it reduce the induction of vWF elicited by the S protein after (Fig. S7C). These results did not point at a major role for TLR4 in HUVEC, thus indicating the existence of other potential receptors for the S protein in this cell type.

Discussion

In this study we demonstrate that SARS-CoV-2 S protein can act as an isolated element that stimulates per se pro-inflammatory and pro-coagulant responses in human primary cultures of monocytes and endothelial cells. In both cell types, the viral protein activates NF-κB, a major regulator of inflammatory responses, and triggers the NLRP3 inflammasome signaling pathway, as a first line innate immunity sensor. All of this is paralleled by the synthesis and release of soluble pro-inflammatory cytokines and an imbalanced production of coagulation regulators.

Hyperinflammation is a key feature of severe COVID-19, where monocytes play a crucial role in the complications driven by the disease [37]. Here we identify S protein as a direct stimulator of monocyte activation by triggering the NF-κB pathway and releasing cytokines such as IL-6, which is elevated in the circulation of COVID-19 patients where it correlates with T cell depletion [37]. In human monocytes, S protein also stimulates the expression of NLRP3 inflammasome components driven by NF-κB [38] and causes the assembly of the active complex leading to the generation and release of active IL-1β. We observed that not only monocytes, but also human endothelial cells released NLRP3 inflammasome-derived IL-1β when challenged with the viral S protein. In this cell type the presence of basal levels GSDMD-NT, which were not further stimulated by S protein or IL-1β, suggest that cell membrane pores may be available for the release of IL-1β to the extracellular space. However, other mechanisms for exporting IL-1β cannot be discarded since inflamed endothelial cells release extracellular vesicles which contain cytokines and other pro-inflammatory mediators [39]. In monocytes and endothelial cells extracellular IL-1β activates itself the NLRP3 inflammasome [30]. Thus, by promoting the synthesis and release of IL-1β, the viral S protein initiates an auto-inflammatory loop that amplifies the local production of the cytokine by different cell types. In terms of pathophysiology, the over-activation of the NLRP3 inflammasome in vascular cells has been tightly associated with vascular diseases, such as atherosclerosis, stroke or hypertension, and, more recently, with COVID-19-associated vasculopathy and hyperinflammation [40, 41].

Overall, the SARS-CoV-2 S protein as an isolated element can be sensed by the cellular innate immune system to produce active IL-1β. Importantly, this pro-inflammatory cytokine has revealed itself as a pivotal player in human vascular disease and atherosclerosis. The CANTOS trial demonstrated that specifically targeting IL-1β with the monoclonal antibody canakinumab reduced chronic low-grade inflammation and the incidence of cardiovascular events, independently of other factors such as hyperlipidemia [42]. Thus, the local production and release of IL-1β from human vascular cells and monocytes stimulated by the S protein may contribute to vascular dysfunction in the context of COVID-19, favoring vascular inflammation and perhaps amplifying and aggravating pre-existing vascular lesions.

In a close relation with hyperinflammation, hypercoagulation and thrombotic events are acknowledged as major complications in COVID-19 and post-COVID-19 patients [43, 44], and they represent rare but challenging adverse effects of S protein mRNA-based vaccines [45]. Interestingly, post-vaccine complications have been recently related to elevated levels of circulating levels of S protein [46]. In this pathological context, vWF, a key coagulation factor formed within endothelial cells and megakaryocytes, has been repeatedly reported elevated in the circulation of COVID-19 patients [47, 48], where it acts as a marker of endotheliopathy and a predictor of poor outcome [49].

Once released, vWF can assemble into filamentous multimers with a high coagulant activity that promote platelet adhesion and aggregation [50]. To avoid excessive thrombogenic activity, the protease ADAMST-13, a physiological regulator of hemostasis, trimers the vWF multimers into smaller and less active molecules [50]. Here, we observed that while both S protein and IL-1β augmented the endothelial content of vWF and its release to the extracellular space, only the cytokine was capable of a parallel induction of ADAMTS-13 in order to counteract the pro-coagulant capacity of vWF. In other words, in human endothelial cells the viral S protein evokes a disbalance in the vWF:ADAMTS-13 ratio which may favor thrombi formation, similar to that observed in certain pro-coagulant and pro-thrombotic conditions such as thrombotic thrombocytopenic purpura or stroke [50, 51]. Indeed, lower ADAMS-13 levels have been described in COVID-19 patients where an elevated vWF:ADAMST-13 ratio strongly correlates with the severity of the disease and associates with endotheliopathy and immune dysfunction in long COVID syndrome [52,53,54].

In parallel, S protein increased the endothelial content of other factors involved in coagulant responses such as FVIII and TF, that are equally associated with hypercoagulability in COVID-19 patients [55,56,57]. The latter was also over-expressed in monocytes, where the S protein behaved similarly to a series of pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) massively released in COVID-19 that induce TF expression in leukocytes and non-immune cells, favoring a hypercoagulable state and thrombus formation [56].

The pharmacological inhibition of the NLRP3 inflammasome activation or the blockade of IL-1R tended to attenuate the endothelial over-expression of coagulation factors induced by the S protein. In monocytes, NLRP3 inflammasome is known to mediate TF release, which is a primary initiator of the coagulation cascade [58]. Thus, an intimate relationship seems to exist between the pro-inflammatory and pro-coagulant activities of the S protein of the SARS-CoV-2 crown, which opens the field for different pharmacological interventions to interfere with the deleterious activation exerted by such an isolated SARS-CoV-2 element on human vascular and immune cells (Fig. 6). In this line, a recent study unveiled a spontaneous NLRP3 inflammasome over-activation and IL-1β secretion in monocytes from severe COVID-19 patients that could be reverted by treating the patients with the IL-1 receptors blocker anakinra [59].

Fig. 6
figure 6

Diagram of cellular pathways activated by SARS-CoV-2 S protein and the targets for pharmacological interference. In human monocytes and HUVEC, S protein as an isolated element activates NF-κB, promotes the release of pro-inflammatory cytokines and triggers the priming and activation of the NLRP3 inflammasome system, leading to the formation and release of mature IL-1β. This cytokine can in turn act on IL-1R, thus fueling and amplifying an auto-inflammatory loop. Moreover, S protein enhances the cellular content of factors involved in coagulation processes, including vWF, FVIII and TF. In human endothelial cells, S protein fails to over-express the protease ADAMS-13 in order to counteract the hypercoagulation capacity of vWF multimers. While these effects of S protein are mediated by TLR4 in human monocytes, the receptors involved in HUVEC remain to be elucidated. Drugs such as anakinra, TAK242 (resotorvid), MCC950, or anti-coagulant drugs could interfere with the deleterious pro-inflammatory and pro-coagulant actions of S protein

Full size image

The activation of the NLRP3 inflammasome was achieved by the whole S protein but not by its isolated S1 fragment which contains the domain binding region (DBR) that interacts with host receptors. While this contradicts some pre-existing studies reporting a functional role for S1 [29, 60, 61], our observation suggests that the homotrimeric S1 structure or even the whole S protein is required to interact with cellular receptors triggering intracellular signaling that leads to the activation of human endothelial and immune cells. Indeed, the whole S protein is the main product of mRNA vaccines developed against COVID-19 [62, 63]. By directly activating immune and endothelial cells from a certain concentration threshold, the S protein could be at the basis of adverse effects related to COVID-19 vaccination, especially in subjects with reported or subclinical endothelial dysfunction or immune disbalance.

Although ACE2 was early identified as a main cell receptor interacting with the S protein of the SARS-CoV-2 corona, it was not detectable in the primary human monocyte cultures used in this study, in line with previous reports showing highly restricted expression of ACE2 primary human immune cells [64, 65]. A similar finding was made in primary endothelial cultures, a cell type for which controversial reports exists regarding the presence or not of ACE2 [66, 67].

Other receptors may favour the recognition and interaction of S-protein with host cells, including toll-like receptor 4 (TLR4), basigin (CD147), and dipeptydilpeptidase-4 (CD26) [7, 64, 68]. Monocytes present constitutive surface expression of TLR4, which is the canonical receptor implicated in the recognition of as bacterial lipopolysaccharides and has been implicated in various diseases [69,70,71]. Ligand binding to TLR4 leads to its oligomerization which in turn can activate myeloid differentiation factor 88 (MYD88) pathway, culminating in the activation of transcription factor NF-κB [72]. In such a context, blocking TLR4 signalling, which has been proposed as a possible therapeutic approach in COVID-19 patients [73], arises as a relevant option to attenuate the direct actions of the S protein as an isolated viral element. Moreover, the fact that TLR4 did not mediate the direct actions of the S protein in endothelial cells underpins the diversity and complexity of the SARS-CoV-2-host interactions and demands further research for better understanding the interactions of the viral protein with a key vascular component such is the endothelium.

Beyond acute COVID-19 episodes, S protein could play a role in the context of COVID sequalae that have been recently associated to persisting circulating levels of the protein [74]. Moreover, SARS-CoV-2 reservoirs have been detected in tissues of post-COVID-19 patients [75]. Years after SARS-CoV-2 viral infection, the S protein, with no other parts of the virus, has been found in organs like the brain [76] in association with persistent local inflammation and vascular damage. Although these studies did not recruit patients diagnosed with long COVID-19, we hypothesize that a non-resolved and sustained endothelial and immune inflammation together with hypercoagulation and thrombosis mediated by the S protein might be a contributor of long-term sequalae. Since blood vessels traverse every organ and immune cells are present in every tissue, both cell types can be key unifying players in a wide variety of prolonged symptoms of the disease.

Taken together, the findings of the present highlight the role of SARS-CoV-2 S protein as an ethiopatogenic agent in the clinical manifestations in acute or long COVID-19 and raises opportunities for novel pharmacological interventions based on S protein blockade, NLRP3 inhibition, monoclonal antibodies or fusion proteins against IL-1β or IL-1R and TLR4 antagonists, among other, together with anticoagulant therapies.

In conclusion, the S protein from SARS-CoV-2 acts as a unifying stimulus directly promoting pro-inflammatory and pro-coagulant activation of human immune and endothelial cells. Interfering with the S protein-host receptor binding or attenuating the deleterious signaling triggered by this isolated viral element might provide therapeutical approaches to confront COVID-19 vaccine-derived complications or acute and long-term complications of the disease.

Availability of data and materials

All data generated and analyzed during the current study are available from corresponding author on reasonable request.

Change history

Abbreviations

COVID-19:

coronavirus disease 2019

SARS-CoV-2:

severe acute respiratory syndrome corona virus 2

S protein:

spike protein

RBD:

receptor binding domain

ACE2:

angiotensin converting enzyme 2

TLR4:

toll-like receptor 4

CD:

cluster differentiation

vWF:

von Willebrand factor

FVIII:

factor VIII

TF:

tissue factor

NLRP3:

NLR family pyrin domain-containing 3

IL:

interleukin

ASC:

apoptosis-associated speck-like protein

HUVEC:

human umbilical vein endothelial cells

PBMC:

peripheral blood mononuclear cell

pp65:

phosphorylated-p65

NF-κB:

nuclear factor-kappa B

ADAMST-13:

A disintegrin and metalloprotease with a thrombospondin type-1 motif, member 13

TNF-α:

tissue necrosis factor alpha

RT-qPCR:

real time quantitative polymerase chain reaction

siTLR4:

specific TLR4 short interfering RNA

References

  1. World Health Organization. COVID-19 epidemiological update (Edition 160). 2023. [cited 2023 October 28]. Available from: https://www.who.int/publications/m/item/covid-19-epidemiological-update---27-october-2023.

  2. Wang C, Ramasamy A, Verduzco-Gutierrez M, Brode WM, Melamed E. Acute and post-acute sequelae of SARS-CoV-2 infection: a review of risk factors and social determinants. Virol J. 2023;20:124.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Huang Y, Yang C, Xu XF, Xu W, Liu SW. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin. 2020;41:1141–9.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Watanabe Y, Allen JD, Wrapp D, McLellan JS, Crispin M. Site-specific glycan analysis of the SARS-CoV-2 spike. Science. 2020;369:330–3.

  5. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L, Wang X. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581:215–20.

    Article  CAS  PubMed  Google Scholar 

  7. Wang K, Chen W, Zhang Z, Deng Y, Lian JQ, Du P, Wei D, Zhang Y, Sun XX, Gong L, et al. CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. Signal Transduct Target Ther. 2020;5:283.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Valencia I, Peiro C, Lorenzo O, Sanchez-Ferrer CF, Eckel J, Romacho T. DPP4 and ACE2 in diabetes and COVID-19: therapeutic targets for cardiovascular complications? Front Pharmacol. 2020;11:1161.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Avolio E, Carrabba M, Milligan R, Kavanagh Williamson M, Beltrami AP, Gupta K, Elvers KT, Gamez M, Foster RR, Gillespie K, et al. The SARS-CoV-2 spike protein disrupts human cardiac pericytes function through CD147 receptor-mediated signalling: a potential non-infective mechanism of COVID-19 microvascular disease. Clin Sci (Lond). 2021;135:2667–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Gu SX, Tyagi T, Jain K, Gu VW, Lee SH, Hwa JM, Kwan JM, Krause DS, Lee AI, Halene S, et al. Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation. Nat Rev Cardiol. 2021;18:194–209.

    Article  CAS  PubMed  Google Scholar 

  11. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Menter T, Haslbauer JD, Nienhold R, Savic S, Hopfer H, Deigendesch N, Frank S, Turek D, Willi N, Pargger H, et al. Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction. Histopathol. 2020;77:198–209.

    Article  Google Scholar 

  13. Martinez-Salazar B, Holwerda M, Studle C, Piragyte I, Mercader N, Engelhardt B, Rieben R, Doring Y. COVID-19 and the vasculature: current aspects and long-term consequences. Front Cell Dev Biol. 2022;10:824851.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Zanini G, Selleri V, Roncati L, Coppi F, Nasi M, Farinetti A, Manenti A, Pinti M, Mattioli AV. Vascular "long COVID": a new vessel disease? Angiol. 2023;18:33197231153204.

  15. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368:473–4.

    Article  CAS  PubMed  Google Scholar 

  16. Jackson SP, Darbousset R, Schoenwaelder SM. Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms. Blood. 2019;133:906–18.

    Article  CAS  PubMed  Google Scholar 

  17. Diaz-Garcia E, Garcia-Tovar S, Alfaro E, Zamarron E, Mangas A, Galera R, Ruiz-Hernandez JJ, Sole-Violan J, Rodriguez-Gallego C, Van-Den-Rym A, et al. Role of CD39 in COVID-19 severity: dysregulation of purinergic signaling and Thromboinflammation. Front Immunol. 2022;13:847894.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Iba T, Levy JH, Connors JM, Warkentin TE, Thachil J, Levi M. The unique characteristics of COVID-19 coagulopathy. Crit Care. 2020;24:360.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Polgar J, Matuskova J, Wagner DD. The P-selectin, tissue factor, coagulation triad. J Thromb Haemost. 2005;3:1590–6.

    Article  CAS  PubMed  Google Scholar 

  20. Bai B, Yang Y, Wang Q, Li M, Tian C, Liu Y, Aung LHH, Li PF, Yu T, Chu XM. NLRP3 inflammasome in endothelial dysfunction. Cell Death Dis. 2020;11:776.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Toldo S, Mezzaroma E, Buckley LF, Potere N, Di Nisio M, Biondi-Zoccai G, Van Tassell BW, Abbate A. Targeting the NLRP3 inflammasome in cardiovascular diseases. Pharmacol Ther. 2022;236:108053.

    Article  CAS  PubMed  Google Scholar 

  22. Ding S, Xu S, Ma Y, Liu G, Jang H, Fang J. Modulatory mechanisms of the NLRP3 Inflammasomes in diabetes. Biomolecules. 2019;9:850.

  23. Diaz-Garcia E, Garcia-Tovar S, Alfaro E, Jaureguizar A, Casitas R, Sanchez-Sanchez B, Zamarron E, Fernandez-Lahera J, Lopez-Collazo E, Cubillos-Zapata C, Garcia-Rio F. Inflammasome activation: a keystone of Proinflammatory response in obstructive sleep apnea. Am J Respir Crit Care Med. 2022;205:1337–48.

    Article  CAS  PubMed  Google Scholar 

  24. Zhao C, Zhao W. NLRP3 Inflammasome-a key player in antiviral responses. Front Immunol. 2020;11:211.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. He Y, Hara H, Nunez G. Mechanism and regulation of NLRP3 Inflammasome activation. Trends Biochem Sci. 2016;41:1012–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. He WT, Wan H, Hu L, Chen P, Wang X, Huang Z, Yang ZH, Zhong CQ, Han J. Gasdermin D is an executor of pyroptosis and required for interleukin-1beta secretion. Cell Res. 2015;25:1285–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Lamkanfi M, Dixit VM. Mechanisms and functions of inflammasomes. Cell. 2014;157:1013–22.

    Article  CAS  PubMed  Google Scholar 

  28. Liu T, Zhang L, Joo D, Sun SC. NF-kappaB signaling in inflammation. Signal Transduct Target Ther. 2017;2:17023.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Perico L, Morigi M, Galbusera M, Pezzotta A, Gastoldi S, Imberti B, Perna A, Ruggenenti P, Donadelli R, Benigni A, Remuzzi G. SARS-CoV-2 spike protein 1 activates microvascular endothelial cells and complement system leading to platelet aggregation. Front Immunol. 2022;13:827146.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Romero A, Dongil P, Valencia I, Vallejo S, Hipolito-Luengo AS, Diaz-Araya G, Bartha JL, Gonzalez-Arlanzon MM, Rivilla F, de la Cuesta F, et al. Pharmacological blockade of NLRP3 Inflammasome/IL-1beta-positive loop mitigates endothelial cell senescence and dysfunction. Aging Dis. 2022;13:284–97.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Romero A, San Hipolito-Luengo A, Villalobos LA, Vallejo S, Valencia I, Michalska P, Pajuelo-Lozano N, Sanchez-Perez I, Leon R, Bartha JL, et al. The angiotensin-(1-7)/mas receptor axis protects from endothelial cell senescence via klotho and Nrf2 activation. Aging Cell. 2019;18:e12913.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Stutz A, Horvath GL, Monks BG, Latz E. ASC speck formation as a readout for inflammasome activation. Methods Mol Biol. 2013;1040:91–101.

    Article  CAS  PubMed  Google Scholar 

  33. Romacho T, Valencia I, Ramos-Gonzalez M, Vallejo S, Lopez-Esteban M, Lorenzo O, Cannata P, Romero A, San Hipolito-Luengo A, Gomez-Cerezo JF, et al. Visfatin/eNampt induces endothelial dysfunction in vivo: a role for toll-like receptor 4 and NLRP3 inflammasome. Sci Rep. 2020;10:5386.

    Article  PubMed  PubMed Central  Google Scholar 

  34. DeYoung V, Singh K, Kretz CA. Mechanisms of ADAMTS13 regulation. J Thromb Haemost. 2022;20:2722–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Foley JH, Conway EM. Cross talk pathways between coagulation and inflammation. Circ Res. 2016;118:1392–408.

    Article  CAS  PubMed  Google Scholar 

  36. Vaez H, Soraya H, Garjani A, Gholikhani T. Toll-like receptor 4 (TLR4) and AMPK relevance in cardiovascular disease. Adv Pharm Bull. 2023;13:36–47.

    CAS  PubMed  Google Scholar 

  37. Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020;20:355–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Bauernfeind FG, Horvath G, Stutz A, Alnemri ES, MacDonald K, Speert D, Fernandes-Alnemri T, Wu J, Monks BG, Fitzgerald KA, et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol. 2009;183:787–91.

    Article  CAS  PubMed  Google Scholar 

  39. Hosseinkhani B, Kuypers S, Van den Akker NM, Molin DG, Michiels L. Extracellular vesicles work as a functional inflammatory mediator between vascular endothelial cells and immune cells. Front Immunol. 2018;9:1789.

    Article  PubMed  PubMed Central  Google Scholar 

  40. van den Berg DF, Te Velde AA. Severe COVID-19: NLRP3 Inflammasome dysregulated. Front Immunol. 2020;11:1580.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Paniri A, Akhavan-Niaki H. Emerging role of IL-6 and NLRP3 inflammasome as potential therapeutic targets to combat COVID-19: role of lncRNAs in cytokine storm modulation. Life Sci. 2020;257:118114.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, et al. Antiinflammatory therapy with Canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–31.

    Article  CAS  PubMed  Google Scholar 

  43. Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020;8:e46–7.

    Article  CAS  PubMed  Google Scholar 

  44. Kole C, Stefanou E, Karvelas N, Schizas D, Toutouzas KP. Acute and post-acute COVID-19 cardiovascular complications: a comprehensive review. Cardiovasc Drugs Ther. 2023:1–16.

  45. Yasmin F, Najeeb H, Naeem U, Moeed A, Atif AR, Asghar MS, Nimri N, Saleem M, Bandyopadhyay D, Krittanawong C, et al. Adverse events following COVID-19 mRNA vaccines: a systematic review of cardiovascular complication, thrombosis, and thrombocytopenia. Immun Inflamm Dis. 2023;11:e807.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Yonker LM, Swank Z, Bartsch YC, Burns MD, Kane A, Boribong BP, Davis JP, Loiselle M, Novak T, Senussi Y, et al. Circulating spike protein detected in post-COVID-19 mRNA vaccine myocarditis. Circulation. 2023;147:867–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Ward SE, Curley GF, Lavin M, Fogarty H, Karampini E, McEvoy NL, Clarke J, Boylan M, Alalqam R, Worrall AP, et al. Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID-19): evidence of acute and sustained endothelial cell activation. Br J Haematol. 2021;192:714–9.

    Article  CAS  PubMed  Google Scholar 

  48. Goshua G, Pine AB, Meizlish ML, Chang CH, Zhang H, Bahel P, Baluha A, Bar N, Bona RD, Burns AJ, et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-Centre, cross-sectional study. Lancet Haematol. 2020;7:e575–82.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Wibowo A, Pranata R, Lim MA, Akbara MR, Martha JW. Endotheliopathy marked by high von Willebrand factor (vWF) antigen in COVID-19 is associated with poor outcome: a systematic review and meta-analysis. Int J Infect Dis. 2022;117:267–73.

    Article  CAS  PubMed  Google Scholar 

  50. Santamaria S, de Groot R. ADAMTS proteases in cardiovascular physiology and disease. Open Biol. 2020;10:200333.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Feys HB, Liu F, Dong N, Pareyn I, Vauterin S, Vandeputte N, Noppe W, Ruan C, Deckmyn H, Vanhoorelbeke K. ADAMTS-13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences. J Thromb Haemost. 2006;4:955–62.

    Article  CAS  PubMed  Google Scholar 

  52. Marco A, Marco P. Von Willebrand factor and ADAMTS13 activity as clinical severity markers in patients with COVID-19. J Thromb Thrombol. 2021;52:497–503.

    Article  CAS  Google Scholar 

  53. Mancini I, Baronciani L, Artoni A, Colpani P, Biganzoli M, Cozzi G, Novembrino C, Boscolo Anzoletti M, De Zan V, Pagliari MT, et al. The ADAMTS13-von Willebrand factor axis in COVID-19 patients. J Thromb Haemost. 2021;19:513–21.

    Article  CAS  PubMed  Google Scholar 

  54. Fogarty H, Ward SE, Townsend L, Karampini E, Elliott S, Conlon N, Dunne J, Kiersey R, Naughton A, Gardiner M, et al. Sustained VWF-ADAMTS-13 axis imbalance and endotheliopathy in long COVID syndrome is related to immune dysfunction. J Thromb Haemost. 2022;20:2429–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Bautista-Vargas M, Bonilla-Abadia F, Canas CA. Potential role for tissue factor in the pathogenesis of hypercoagulability associated with in COVID-19. J Thromb Thrombol. 2020;50:479–83.

    Article  CAS  Google Scholar 

  56. Sachetto TAA, Mackman N. Tissue factor and COVID-19: an update. Curr Drug Targets. 2022;23:1573–7.

    Article  CAS  PubMed  Google Scholar 

  57. Xu X, Feng Y, Jia Y, Zhang X, Li L, Bai X, Jiao L. Prognostic value of von Willebrand factor and ADAMTS13 in patients with COVID-19: a systematic review and meta-analysis. Thromb Res. 2022;218:83–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Zelaya H, Rothmeier AS, Ruf W. Tissue factor at the crossroad of coagulation and cell signaling. J Thromb Haemost. 2018;16:1941–52.

    Article  CAS  PubMed  Google Scholar 

  59. Bertoni A, Penco F, Mollica H, Bocca P, Prigione I, Corcione A, Cangelosi D, Schena F, Del Zotto G, Amaro A. Spontaneous NLRP3 inflammasome-driven IL-1-β secretion is induced in severe COVID-19 patients and responds to anakinra treatment. J Allergy Clin Immunol. 2022;150:796–805.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Schroeder JT, Bieneman AP. The S1 subunit of the SARS-CoV-2 spike protein activates human monocytes to produce cytokines linked to COVID-19: relevance to Galectin-3. Front Immunol. 2022;13:831763.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Guo Y, Kanamarlapudi V. Molecular analysis of SARS-CoV-2 spike protein-induced endothelial cell permeability and vWF secretion. Int J Mol Sci. 2023;24;5664.

  62. Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586:516–27.

    Article  CAS  PubMed  Google Scholar 

  63. Bettini E, Locci M. SARS-CoV-2 mRNA vaccines: immunological mechanism and beyond. Vaccines (Basel). 2021;9:147.

  64. Radzikowska U, Ding M, Tan G, Zhakparov D, Peng Y, Wawrzyniak P, Wang M, Li S, Morita H, Altunbulakli C, et al. Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors. Allergy. 2020;75:2829–45.

    Article  CAS  PubMed  Google Scholar 

  65. Zankharia U, Yadav A, Yi Y, Hahn BH, Collman RG. Highly restricted SARS-CoV-2 receptor expression and resistance to infection by primary human monocytes and monocyte-derived macrophages. J Leukoc Biol. 2022;112:569–76.

    Article  CAS  PubMed  Google Scholar 

  66. McCracken IR, Saginc G, He L, Huseynov A, Daniels A, Fletcher S, Peghaire C, Kalna V, Andaloussi-Mae M, Muhl L, et al. Lack of evidence of angiotensin-converting enzyme 2 expression and replicative infection by SARS-CoV-2 in human endothelial cells. Circulation. 2021;143:865–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Muhl L, He L, Sun Y, Andaloussi Mae M, Pietila R, Liu J, Genove G, Zhang L, Xie Y, Leptidis S, et al. The SARS-CoV-2 receptor ACE2 is expressed in mouse pericytes but not endothelial cells: implications for COVID-19 vascular research. Stem Cell Rep. 2022;17:1089–104.

    Article  CAS  Google Scholar 

  68. Li Y, Zhang Z, Yang L, Lian X, Xie Y, Li S, Xin S, Cao P, Lu J. The MERS-CoV Receptor DPP4 as a Candidate Binding Target of the SARS-CoV-2 Spike. iScience. 2020;23:101160.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. den Dekker WK, Cheng C, Pasterkamp G, Duckers HJ. Toll like receptor 4 in atherosclerosis and plaque destabilization. Atherosclerosis. 2010;209:314–20.

    Article  Google Scholar 

  70. Yang QW, Li JC, Lu FL, Wen AQ, Xiang J, Zhang LL, Huang ZY, Wang JZ. Upregulated expression of toll-like receptor 4 in monocytes correlates with severity of acute cerebral infarction. J Cereb Blood Flow Metab. 2008;28:1588–96.

    Article  CAS  PubMed  Google Scholar 

  71. Wittebole X, Castanares-Zapatero D, Laterre PF. Toll-like receptor 4 modulation as a strategy to treat sepsis. Mediat Inflamm. 2010;2010:568396.

    Article  CAS  Google Scholar 

  72. Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine. 2008;42:145–51.

    Article  CAS  PubMed  Google Scholar 

  73. Kaushik D, Bhandari R, Kuhad A. TLR4 as a therapeutic target for respiratory and neurological complications of SARS-CoV-2. Expert Opin Ther Targets. 2021;25:491–508.

    Article  CAS  PubMed  Google Scholar 

  74. Swank Z, Senussi Y, Manickas-Hill Z, Yu XG, Li JZ, Alter G, Walt DR. Persistent circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post-acute coronavirus disease 2019 sequelae. Clin Infect Dis. 2023;76:e487–90.

    Article  PubMed  Google Scholar 

  75. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21:133–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Rong Z, Mai H, Kapoor S, Puelles VG, Czogalla J, Schädler J, Vering J, Delbridge C, Steinke H, Frenzel H, et al: SARS-CoV-2 spike protein accumulation in the skull-MeningesBrain Axis: potential implications for long-term neurological complications in post-COVID-19. 2023.

    Google Scholar 

Download references

Acknowledgments

We thank Asier Rubio, MD., for experimental support and the Blood Donor Service of La Paz University Hospital for helping in the recruitment of healthy controls.

Funding

Supported by funds from REACT-EU-Comunidad de Madrid and the European Regional Development Fund (SPACE2-CV-COVID-CM) to C. Peiró and O. Lorenzo, Fondo de Investigación Sanitaria-FIS Carlos III (PI20/00923) to O. Lorenzo, Plan Nacional I + D (PID2020-115590RB-100/AEI/ https://doi.org/10.13039/501100011033) to C. Peiró and C.F. Sánchez-Ferrer, Instituto de Salud Carlos III PI19/01612, PI22/01262 to F. García-Río and CP18/0028, PI19/01363 and PI22/01257 to C. Cubillos-Zapata.

Author information

Author notes

  1. Alicia Villacampa and Enrique Alfaro contributed equally to this study.

Authors and Affiliations

  1. Department of Pharmacology, School of Medicine, Universidad Autónoma de Madrid, Madrid, Spain

    Alicia Villacampa, Cristina Morales, Salvador Moncada, Carlos F. Sánchez-Ferrer & Concepción Peiró

  2. Respiratory Diseases Group, Respiratory Service, La Paz University Hospital, IdiPAZ, Madrid, Spain

    Enrique Alfaro, Elena Díaz-García, Cristina López-Fernández, Francisco García-Río & Carolina Cubillos-Zapata

  3. Biomedical Research Networking Center on Respiratory Diseases (CIBERES), Madrid, Spain

    Enrique Alfaro, Elena Díaz-García, Francisco García-Río & Carolina Cubillos-Zapata

  4. Department of Obstetrics and Gynecology, School of Medicine, Universidad Autónoma de Madrid, Madrid, Spain

    José Luis Bartha

  5. Gynecology and Obstetrics Service, La Paz University Hospital, Madrid, Spain

    José Luis Bartha & Francisco López-Sánchez

  6. Laboratory of Diabetes and Vascular pathology, IIS-Fundación Jiménez Díaz, Madrid, Spain

    Óscar Lorenzo

  7. Biomedical Research Networking Centre on Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain

    Óscar Lorenzo

  8. Department of Medicine, School of Medicine, Universidad Autónoma de Madrid, Madrid, Spain

    Óscar Lorenzo & Francisco García-Río

  9. Vascular Pharmacology and Metabolism (FARMAVASM) group, IdiPAZ, Madrid, Spain

    Carlos F. Sánchez-Ferrer & Concepción Peiró

Authors
  1. Alicia Villacampa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Enrique Alfaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cristina Morales
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elena Díaz-García
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Cristina López-Fernández
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. José Luis Bartha
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Francisco López-Sánchez
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Óscar Lorenzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Salvador Moncada
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Carlos F. Sánchez-Ferrer
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Francisco García-Río
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Carolina Cubillos-Zapata
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Concepción Peiró
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Contribution: A.V., E.A., C.M., E.D-G., and C.L-F. performed experiments, analyzed the data, and revised the manuscript; JL.B. and F.L-S. provided human samples and revised the manuscript; O.L, F.G-R., and CF.S-F conceived experiments, supervised data analysis, interpreted the data, and revised the manuscript; S.M. interpreted the data and revised the manuscript; C.P. and C.C-Z. designed the study, interpreted the data, wrote the manuscript and jointly supervised the study.

Corresponding authors

Correspondence to Carolina Cubillos-Zapata or Concepción Peiró.

Ethics declarations

Ethics approval and consent to participate

The studies involving human participants were reviewed and approved by local ethics committee at La Paz University Hospital (PI-3486 and PI-4087), and informed consent was obtained from all participants.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original version of this article was revised: Co-correspondence information has been updated.

Supplementary Information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Villacampa, A., Alfaro, E., Morales, C. et al. SARS-CoV-2 S protein activates NLRP3 inflammasome and deregulates coagulation factors in endothelial and immune cells. Cell Commun Signal 22, 38 (2024). https://doi.org/10.1186/s12964-023-01397-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12964-023-01397-6

Keywords

Cell Communication and Signaling

ISSN: 1478-811X